[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Olema Pharmaceuticals Inc (OLMA)

Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,003,617
  • Shares Outstanding, K 87,347
  • Annual Sales, $ 0 K
  • Annual Income, $ -162,450 K
  • EBIT $ -202 M
  • EBITDA $ -201 M
  • 60-Month Beta 2.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.11

Options Overview Details

View History
  • Implied Volatility 176.32% (+63.32%)
  • Historical Volatility 54.94%
  • IV Percentile 75%
  • IV Rank 36.97%
  • IV High 416.48% on 11/14/25
  • IV Low 35.47% on 09/02/25
  • Expected Move (DTE 28) 0.00 (0.00%)
  • Put/Call Vol Ratio 3.10
  • Today's Volume 41
  • Volume Avg (30-Day) 468
  • Put/Call OI Ratio 2.33
  • Today's Open Interest 12,779
  • Open Int (30-Day) 11,807
  • Expected Range 11.74 to 11.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.53
  • Number of Estimates 4
  • High Estimate $-0.45
  • Low Estimate $-0.57
  • Prior Year $-0.51
  • Growth Rate Est. (year over year) -3.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.35 +13.48%
on 06/24/26
13.09 -10.31%
on 07/07/26
+1.21 (+11.49%)
since 06/23/26
3-Month
9.06 +29.58%
on 06/18/26
16.02 -26.72%
on 04/27/26
-3.61 (-23.52%)
since 04/23/26
52-Week
4.47 +162.64%
on 08/11/25
36.26 -67.62%
on 12/16/25
+7.08 (+151.93%)
since 07/23/25

Most Recent Stories

More News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, July 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 11.74 (+2.18%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 11.74 (+2.18%)
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

Study to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 First clinical collaboration for OP-3136; results...

OLMA : 11.74 (+2.18%)
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across...

OLMA : 11.74 (+2.18%)
Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 11.74 (+2.18%)
Olema Oncology Reports First Quarter 2026 Financial and Operating Results

Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients First clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended...

OLMA : 11.74 (+2.18%)
Olema Pharmaceuticals Reports Tomorrow, Where Another Quarter of Losses Counts as Clinical Progress

Barchart Research What to Expect from OLMA Earnings OLMA Generated May 11, 2026 Current Price $14.86 EPS Estimate $$-0.52 Consensus Rating Strong Buy Average Move 6.96% Olema Pharmaceuticals Reports Tomorrow,...

OLMA : 11.74 (+2.18%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 11.74 (+2.18%)
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 11.74 (+2.18%)
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 11.74 (+2.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California....

See More

Key Turning Points

3rd Resistance Point 13.18
2nd Resistance Point 12.48
1st Resistance Point 12.11
Last Price 11.74
1st Support Level 11.04
2nd Support Level 10.34
3rd Support Level 9.97

See More

52-Week High 36.26
Fibonacci 61.8% 24.12
Fibonacci 50% 20.36
Fibonacci 38.2% 16.61
Last Price 11.74
52-Week Low 4.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.